ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BAYRY Bayer Aktiengesellschaft (PK)

7.60
0.24 (3.26%)
02 May 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Bayer Aktiengesellschaft (PK) USOTC:BAYRY OTCMarkets Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.24 3.26% 7.60 7.60 7.64 7.674 7.53 7.64 2,607,824 21:00:01

Judge Cuts $55 Million From $80 Million Roundup Verdict -- Update

15/07/2019 11:33pm

Dow Jones News


Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Bayer Aktiengesellschaft (PK) Charts.
By Sara Randazzo 

A federal judge Monday cut down by $55 million a verdict tying Bayer AG's Roundup weedkiller to cancer, as the company continues to battle thousands of similar claims in the U.S.

The ruling comes in the case of Northern California resident Edwin Hardeman, who won a more than $80 million jury verdict in a case linking his non-Hodgkin lymphoma to yearslong Roundup use on his residential properties. His March trial was the second of three that Bayer has lost over the safety of Roundup, a product it acquired last year through its purchase of Monsanto Co.

U.S. District Judge Vince Chhabria said the $75 million in punitive damages awarded to Mr. Hardeman by the six-person jury was excessive compared with the $5.3 million in other damages. The judge said $20 million in punitive damages, or roughly four times the compensatory damages, was more appropriate under U.S. Supreme Court guidelines.

"Based on the evidence that came in at trial, Monsanto deserves to be punished," Judge Chhabria wrote in his Monday ruling. The judge concluded that while the science is still mixed on whether glyphosate, the active ingredient in Roundup, causes non-Hodgkin lymphoma, the company didn't seem to care about investigating whether its product may be carcinogenic.

"While Monsanto repeatedly intones that it stands by the safety of its product, the evidence at trial painted the picture of a company focused on attacking or undermining the people who raised concerns," he wrote.

Bayer said Monday the reduction of the damages is a step in the right direction but that it still plans to appeal because the jury's decision conflicts with scientific evidence and the conclusions of health regulators world-wide.

Jennifer Moore, an attorney for Mr. Hardeman, said she disagrees with the reduction of the damages but called it "a major victory" that the judge didn't throw out the verdict entirely as Monsanto requested.

Bayer similarly succeeded in having a trial judge slash the first Roundup jury verdict in the case of a San Francisco Bay Area groundskeeper, to $78.5 million from $289.2 million. The company is now appealing that slimmed-down amount. Bayer is asking a judge to reduce a third jury verdict, also in Northern California, of more than $2 billion awarded in May to a couple who used Roundup at their home.

In Mr. Hardeman's trial, unlike in the other two, jurors first weighed whether science showed a link between Roundup and his non-Hodgkin lymphoma before turning to the question of Monsanto's liability.

The trio of jury verdicts and 13,000 additional claims tying Roundup to cancer have sent German-based Bayer into turmoil. Its shares have lost over 30% in value over the past year as investors worry the legal battle could take years to resolve and end up costing Bayer billions.

Analysts are closely watching the first cases moving through the appeals process in search of clues to estimate total liabilities. Bayer hasn't booked any liabilities yet.

Bayer says Roundup and glyphosate are safe and argues that more than 800 scientific studies and decisions by regulators around the world back up that view. The chemical has been under intense scrutiny since 2015, when the International Agency for Research on Cancer, a World Health Organization unit, classified glyphosate as "probably carcinogenic to humans."

During a July 2 hearing in San Francisco, Judge Chhabria said he was constitutionally required to reduce the damages in Mr. Hardeman's case. He said in court that "Monsanto didn't seem concerned at all with getting at the truth of whether Roundup caused cancer."

After the hearing, one of the jurors in the case wrote a letter to Judge Chhabria urging him not to reduce the verdict. "Every single decimal in those numbers is the result of conscious collaboration and calculated, deliberate efforts by all six of us," the juror, whose name wasn't publicly released, wrote, adding that the deliberations included "some of the toughest decisions we have ever made."

Bayer said in a court filing the judge shouldn't consider the juror's letter and that it, along with similar letters jurors wrote to the judge overseeing the first trial, "generates further anti-Monsanto bias in the Bay Area that will infect future Roundup trials."

The next Roundup trials are scheduled for August and September in St. Louis County.

--Ruth Bender contributed to this article.

Write to Sara Randazzo at sara.randazzo@wsj.com

 

(END) Dow Jones Newswires

July 15, 2019 18:18 ET (22:18 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Bayer Aktiengesellschaft (PK) Chart

1 Year Bayer Aktiengesellschaft (PK) Chart

1 Month Bayer Aktiengesellschaft (PK) Chart

1 Month Bayer Aktiengesellschaft (PK) Chart

Your Recent History

Delayed Upgrade Clock